Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.815 AUD | +6.14% | -10.15% | +116.07% |
Valuation
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 199.8 | 291.2 | - | - |
Enterprise Value (EV) 1 | 199.8 | 281.9 | 257.7 | 269.7 |
P/E ratio | -19.9 x | -23.8 x | -21.6 x | -18.6 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | 72.8 x | 67.7 x | 57.1 x |
EV / Revenue | - | 70.5 x | 59.9 x | 52.9 x |
EV / EBITDA | - | -24.3 x | -19.4 x | -17.5 x |
EV / FCF | - | -24.7 x | -19.5 x | -17.5 x |
FCF Yield | - | -4.04% | -5.12% | -5.71% |
Price to Book | - | 17.1 x | - | 17.1 x |
Nbr of stocks (in thousands) | 163,069 | 170,284 | - | - |
Reference price 2 | 1.225 | 1.710 | 1.710 | 1.710 |
Announcement Date | 23-08-30 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | 4 | 4.3 | 5.1 |
EBITDA 1 | - | -11.6 | -13.3 | -15.4 |
EBIT 1 | - | -11.9 | -13.6 | -15.7 |
Operating Margin | - | -297.5% | -316.28% | -307.84% |
Earnings before Tax (EBT) 1 | - | -11.7 | -13.5 | -15.7 |
Net income 1 | -9.923 | -11.7 | -13.5 | -15.7 |
Net margin | - | -292.5% | -313.95% | -307.84% |
EPS 2 | -0.0617 | -0.0720 | -0.0790 | -0.0920 |
Free Cash Flow 1 | - | -11.4 | -13.2 | -15.4 |
FCF margin | - | -285% | -306.98% | -301.96% |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 23-08-30 | - | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | - | 9.3 | 33.5 | 21.5 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -11.4 | -13.2 | -15.4 |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share 2 | - | 0.1000 | - | 0.1000 |
Cash Flow per Share 2 | - | -0.0700 | -0.0800 | -0.0800 |
Capex 1 | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 23-08-30 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+116.07% | 193M | |
+38.36% | 52.73B | |
+39.10% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- RAC Stock
- Financials Race Oncology Limited